Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
12.79
-0.25 (-1.92%)
At close: Nov 21, 2024, 4:00 PM
12.64
-0.15 (-1.17%)
After-hours: Nov 21, 2024, 4:39 PM EST
Rocket Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
268
Market Cap
1.17B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pediatrix Medical Group | 2.01B |
Indivior | 1.18B |
Novavax | 885.19M |
Tilray Brands | 812.04M |
Innoviva | 352.75M |
CareDx | 312.78M |
Maravai LifeSciences Holdings | 276.92M |
Mesoblast | 5.90M |
RCKT News
- 2 days ago - Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst - Benzinga
- 3 days ago - Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference - Business Wire
- 9 days ago - Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions - Business Wire
- 13 days ago - Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference - Business Wire
- 14 days ago - Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress - Business Wire
- 2 months ago - Rocket: Danon Disease Treatment Program Should Carry The Tide Until Regulatory Moves - Seeking Alpha
- 2 months ago - Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease - Business Wire
- 2 months ago - Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors - Business Wire